Mycophorol™: Patent Pending – PATP1280.01 / 1280.04 – Application Number 19/381439

Biotech International Institute is at the forefront of advancing a new line of testing in neuroscience chemistry. The incredible diversity of synthetic microbiology inspires this initiative, and one of the flagship research candidates in this effort is Mycophorol™, a fungal-derived hybrid molecule developed solely for preclinical investigation.

Mycophorol™ is not yet authorized for medical use, and cannot be drawn at this stage; no conclusions regarding safety, efficacy, or therapeutic potential can be made. The program currently exists to ask scientific questions, not to provide treatments.

What Is Mycophorol™?

Mycophorol™ is a novel, patent-pending hybrid molecule that combines two primary inspirations from mushroom science:

Psilocybin-inspired tryptamine motif, reflecting structural elements found in classic indole-based neuroactive compounds.
Hericenone-related structures are associated with Lion's Mane (Hericium erinaceus), a mushroom of longstanding interest in ethnobotanical and modern research contexts.

These components are joined using a biocompatible chemical linker, forming a single molecular platform that can be studied as a unified way rather than as a simple mixture of compounds.

The core of the Mycophorol™ program centers on:

Synthetic route design and optimization
Rigorous chemical characterization
Early-stage in vitro and preclinical exploratory assays

The focus is on mechanism-oriented analysis, not on product development for human use.

Key Areas of Investigation

The Mycophorol™ research will track the organization around a set of mechanistic questions that can be probed in controlled laboratory settings. Current and planned studies aim to understand the following domains better:

1. Receptor Interactions

Researchers will studying how Mycophorol™ interacts with serotonin-family receptors, including but not limited to 5-HT₂A, in vitro.

Mapping binding profiles and functional responses
Comparing activity to known reference compounds
Exploring structure-activity relationships within the hybrid scaffold

These studies are strictly preclinical and are designed to clarify receptor-level engagement, not clinical outcomes.

2. Neurotrophic Pathways

Another line of research assesses whether Mycophorol™ exposure is associated with measurable changes in neurotrophic markers, such as brain-derived neurotrophic factor (BDNF), under tightly controlled testing conditions.

Cell-based assays to track changes in relevant signaling pathways
Time- and concentration-dependent response profiling
Exploration of potential links between receptor activity and trophic markers

Any observed correlations remain hypothesis-generating and do not demonstrate benefit in humans or animals.

Neuroinflammation Models

Inflammatory processes are increasingly recognized as necessary in neurological research. Mycophorol™ will be evaluated in standard in vitro neuroinflammation models to observe:

Its behavior in cellular systems exposed to pro-inflammatory stimuli
Potential modulation of specific signaling cascades or readouts

These investigations help clarify how the molecule behaves in inflammatory signaling environments, without implying disease treatment or prevention.

Cognition-Related Readouts

The program is also assessing which preclinical models of learning and memory proxies might be suitable for future, mechanism-focused work with Mycophorol™.

Key points:

These models are proxies only; they cannot be used to infer clinical cognition outcomes.
Any signal observed would be used to refine hypotheses and experimental design, not to support therapeutic claims.

It's important to note that across all these domains, the work is explicitly exploratory and does not establish clinical benefit.

How This Program Differs

A unique feature of the Mycophorol™ initiative is its integrated molecular design system. Instead of studying psychedelic-inspired analogs and non-psychedelic mushroom metabolites separately, Biotech International Institute has chosen to:

Combine these inspiration sources into a single, designed hybrid scaffold
Use that scaffold to interrogate multiple mechanistic hypotheses at once

This contrasts with more conventional single-target approaches that focus on individual receptor subtypes or isolated mechanisms.

Within the laboratory context, researchers will also be examining a variety of formulation concepts, including:

Sublingual-style research prototypes
Nanoemulsion-based dispersions
Extended-release experimental formats

All such formulations are strictly for laboratory and preclinical use only, not for human consumption or clinical deployment.

Development Status

Mycophorol™ is currently:

Patent-pending, with relevant applications filed (PATP1280.01 / 1280.04; APP Number 19/381439).
In the preclinical research phase, with work focused on:

Synthetic chemistry routes and scale-up feasibility

Stability and degradation profiling

Mechanism-oriented in vitro and early model assessments

Any potential future development, whether deeper preclinical work, regulatory filings, or clinical studies, if ever pursued, would follow standard scientific and regulatory pathways. At this time:

No therapeutic claims are made.
No conclusions about safety, efficacy, or appropriate use can be drawn.

Scientific Positioning

Two complementary knowledge streams inform the Mycophorol™ program:

Ethnobotanical and ethnomycological literature

Historical accounts and traditional uses of certain fungi provide context and inspiration for molecular design.

These references are historical only and must not be interpreted as evidence of safety or efficacy.

Modern synthetic biology and medicinal chemistry

Contemporary tools in organic synthesis, molecular modeling, and analytical chemistry guide the construction and evaluation of the hybrid scaffold.

Data from ongoing experiments are used to refine hypotheses, not to market a finished product.

This positioning reflects Biotech International Institute's goal of bridging traditional knowledge and cutting-edge science in a rigorous, regulatory-conscious manner.

Collaboration & Partnership Opportunities

Biotech International Institute is actively exploring collaborations around Mycophorol™ and related platforms, particularly in the areas of:

Chemistry & synthetic strategies
Analytical method development (e.g., LC–MS, NMR, stability-indicating methods)
Preclinical methodology, including assay design, model selection, and data interpretation

Qualified partners in academia and industry are invited to discuss:

Joint research projects
Assay and biomarker development
Platform evaluation and technology exchange

Any cooperation is structured to respect:

Intellectual property (IP) rights
Regulatory expectations
Ethical standards specific to neurological and psychedelic-adjacent research

Intellectual Property

Patent applications related to Mycophorol™ have been filed, and all rights are reserved by Biotech International Institute and the named inventors, Bill Carrington and Dominic Carrington.

Key points regarding IP:

"Patent pending" indicates that an application has been submitted; it does not guarantee that a patent will be granted or define the final scope of protection.
Any collaboration or data-sharing activity will be designed to align with:

Existing and future IP protections

Confidentiality needs

Relevant compliance frameworks

Important Notices & Disclaimers

To ensure clarity around the scope and intent of the Mycophorol™ program:

No medical claims

The information presented here describes only research concepts, goals, and status.

It does not assert safety, efficacy, or clinical benefit for any condition.

Not a substitute for care

Nothing in this article constitutes medical advice, diagnosis, or treatment.

Individuals should consult qualified healthcare professionals for any medical concerns.

Forward-looking statements

Plans and expectations for the Mycophorol™ program may change in response to new data, evolving scientific understanding, and regulatory feedback.

Any future directions discussed are exploratory and not guaranteed.

IP status

"Patent pending" reflects a filed application and does not imply issuance, enforceability, or specific claim coverage.